Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06218069 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Study acronym: IMPRINT
StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 29, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: May 2025 to Dec 2025
    • Start date: Aug 2024 to Feb 2025
    v3
  2. Start date: Mar 2024 to Aug 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study investigates whether a single subcutaneous administration of anti-PD-1 antibody can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with \[89Zr\]crefmirlimab berdoxam PET imaging as an imaging biomarker.
Trial Details
NCT Number NCT06218069
Lead Sponsor Radboud University Medical Center
Collaborators: Pfizer, ImaginAb, Inc., University Hospital Tuebingen
Conditions
(from sponsor)		 NSCLC
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov